Medtronic earnings preview: $1.34 EPS and $9.47bn revenue expected on Tuesday

Medtronic earnings preview: $1.34 EPS and $9.47bn revenue expected on Tuesday

ShareWhatsAppFacebookXLinkedInTelegram

Medtronic is expected to report fiscal second-quarter earnings of $1.34 a share on $9.47bn of revenue before the US open on Tuesday 24 November, according to an Earnings Whispers preview. That implies sales growth of 5.7% but earnings per share 1.5% lower than the $1.36 of a year ago.

Loading live price…

What does Wall Street expect from Medtronic?

The company confirmed the date and the quarter, which ended 30 October 2026, in its own announcement. The unofficial whisper figure is $1.37, a few cents above consensus. Full-year guidance is EPS of $5.94 to $6.00 and revenue of $39.00bn to $39.18bn. Consensus for the year is $5.94, at the bottom of the guided EPS range, and revenue of $38.64bn sits below the guided range, the preview says.

That gap is the setup: the Street is slightly cautious versus management, so a clean quarter could lead analysts to move up to the guidance. The Stock Titan calendar lists the same $1.34 consensus.

Is the growth real or helped by the calendar?

The last quarter showed about 7% organic growth, but it was boosted by a 53rd selling week that added about $570m, or roughly 670 basis points. This is the first quarter without that help, so the preview frames the test as whether roughly 7% organic growth is sustainable. If underlying growth drops sharply, shares that have run ahead of the market could pay for it.

Which products and costs matter most?

  • Cardiac ablation: the outlook was raised to more than 2.5 times market growth for the year, and more than 3 times in the second quarter. It is the standout product line.
  • Diabetes: Zacks expects strong US growth after the MiniMed Flex with Simplera Sync launch, per its preview.
  • Neuromodulation: grew 3% last quarter, weighed down by spinal cord stimulation.
  • Margins: expected operating-margin expansion was trimmed to about 50 basis points from 60, partly because of foregone interest on a $700m investment in Cornerstone Robotics.

How has the stock performed?

Shares were $102.86, up 9.4% since the last report while the S&P 500 fell 1%, with the 200-day average at $88.32 and the post-earnings high at $106.20. Bullish sentiment fell to 18.5% from 26.2%. Medtronic has also beaten EPS estimates in each of the last four quarters, by an average of about 2.8%, Zacks reports. A long record of small beats means a modest beat may already be in the price. For how a multiple frames expectations, see what is a P/E ratio.

Investors also have an investor day to look forward to on 10 and 11 December, the preview notes, so the company may save longer-term messages for then. The call on Tuesday is likely to focus on guidance for the second half.

Why does a healthcare name matter in an AI sell-off?

Last week was brutal for growth and technology shares: the S&P 500 fell 8.6% and the Nasdaq Composite 10.0%, STL.News reported. Defensive sectors like medical devices are often watched for signs of rotation. Whether Medtronic can hold its gains during a market correction is a useful gauge of how much of the market’s fall is about AI and how much is about higher rates. Our report on the S&P 500 correction has the full week.

The 10-year Treasury yield fell about 12 basis points to around 4.93% on Friday, per the same source. A lower yield helps long-duration, steady-earning companies, but a Fed hike in December would still weigh. See Fed hike odds near 97%.

What is the South African angle?

South African investors buy medical-device groups like Medtronic through offshore allowances or global ETFs. The rand was near R17.35 per dollar on Thursday, BusinessTech reported, so a flat dollar share price still shows a gain in rand terms for holders. Track the currency on our dollar to rand today page, and browse more in the Stocks and S&P 500 section.

Watch the second-half guide, the organic-growth rate without the extra week, and the ablation commentary. Those three items will set the tone.

What would a good report look like?

A good quarter would pair organic growth near the 7% pace with an unchanged or raised full-year guide, plus evidence that ablation is still taking share. A miss on organic growth would raise the question of how much of the previous quarter came from the extra week. The company’s mix of products also means a weak line, such as spinal cord stimulation, can offset a strong one. Either way, the full-year guidance range of $5.94 to $6.00 is the figure that most analysts will compare with their models, because consensus already sits at its floor.

Because the stock has risen 9.4% since the last report while the broader market fell, a lot of good news is arguably in the price. That does not mean the shares must fall; it means the bar is higher than the 5.7% revenue growth number suggests.

Trade the markets you read about. Open a free WiseProp Trader account, with no deposit.

This article is for education and information only and is not financial advice. Figures are as reported by the sources linked above.

Found this useful? Share itWhatsAppFacebookXLinkedInTelegram
Free daily email
3 things moving markets

The three stories that matter, in your inbox at 07:00. One email a day, unsubscribe any time.

By subscribing you agree to receive the WiseProp Trader News email. We will ask you to confirm first. See our privacy policy.